No summary available.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5th, at 12:20 p.m. Eastern Time. The fire-side chat presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcast will be Jetzt den vollständigen Artikel lesen

Hologic to present at Morgan Stanley Healthcare Conference. Learn about the women''s health tech leader''s latest developments. Live webcast available Sept 5, 12:20 PM ET. Don''t miss this opportunity for valuable industry insights.

No summary available.

Hologic (NASDAQ: HOLX ) has outperformed the market over the past 10 years by 1.79% on an annualized basis producing an average annual return of 12.59%. Currently, Hologic has a market capitalization of $18.90 billion. Buying $1000 In HOLX: If an … Full story available on Benzinga.com

https://www.investing.com/news/company-news/hologic-stock-hits-52week-high-soaring-to-8437-93CH-3564984

We recently compiled a list of the 10 Best Cosmetic Surgery and Aesthetics Stocks To Buy. In this article, we are going to take a look at where Hologic, Inc. (NASDAQ:HOLX) stands against the other cosmetic surgery and aesthetics stocks. While imperfections are inherent to being human, aesthetic (or cosmetic) plastic surgery is a viable alternative […]

BURLINGAME, CALIFORNIA, UNITED STATES, August 8, 2024 /⁨EINPresswire.com⁩/ -- The latest research study released by Coherent Market Insights on "Molecular Diagnostics Market 2024" holds tons of experience in offering comprehensive and …

Stephen MacMillan, Hologic CEO, joins ''Money Movers'' to discuss the company''s earnings, how the company is encouraging women to get health screenings, and more.

Hologic, Inc . (NASDAQ: HOLX ) reported upbeat earnings for its third quarter, but issued soft guidance on Monday. Hologic reported quarterly earnings of $1.06 per share which beat the analyst consensus estimate of $1.02 per share. The company reported quarterly sales of $1.011 billion which beat the analyst consensus estimate of $1.000 billion, according to data from Benzinga Pro . “In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Our strong fiscal quarter and year-to-date results … Full story available on Benzinga.com